The information provided on this page is for reference only. Please refer to the latest information published by the partner company.
We are dedicated to the delivery of innovative first-in-class and best-in-class drug discovery, giving most needed support to companies facing risk and technology barriers, to help their innovation with potential to succeed.
Utilising world-class technologies in protein science, VVBI focuses on developing/commercialising antibody fragment drugs, antibody/antibody fragment-drug conjugates, structure-based drug design (SBDD), fragment-based drug design (FBDD), affinity selection mass spectrometry (ASMS) screening technology, and membrane protein targeted drug discovery. VVBI services also include target validation, hit identification, lead discovery, in vitro bioassay, as well as therapeutic antibody discovery.
Our mission is to build, incubate and invest in promising biotechs. We are building biotech platforms for new drug discovery and development, with current focuses on antibody conjugates, novel drug delivery system and new drug clinical trials.
VVBI has benefited from talent recruitment and project funding through the biotech ecosystem established by HKSTP. We both share the commitment to accelerate technological innovation and commercialisation.